These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28025965)

  • 1. Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment
.
    Liu Y; Boettcher MF; Schmidt A; Unger S; Halabi A; Brendel E; Blode H
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):246-255. PubMed ID: 28025965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
    Park DB; Jang K; Lee JW; Park CW; Lee BH; Kim MG; Jeon JY
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):286-294. PubMed ID: 28079517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions.
    Brendel E; Weimann B; Dietrich H; Froede C; Thomas D
    Int J Clin Pharmacol Ther; 2013 Sep; 51(9):753-62. PubMed ID: 23849325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants.
    Kim JH; Song JH; Kim M; Hong JH; Sunwoo J; Jung JG
    Adv Ther; 2024 Jul; 41(7):2808-2825. PubMed ID: 38771476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of bioequivalence, safety, and tolerability of a fixed-dose combination of nifedipine GITS and candesartan compared with the corresponding loose-dose combination under fed conditions
.
    Thomas D; Liu Y; Stein H; Weimann B
    Int J Clin Pharmacol Ther; 2019 Aug; 57(8):420-428. PubMed ID: 31232274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects.
    Sunkara G; Jiang X; Reynolds C; Serra D; Zhang Y; Ligueros-Saylan M; Ayalasomayajula S; Winter S; Jarugula V
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):487-92. PubMed ID: 27129123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers.
    Nam JH; Oh M; Kim HJ; Han SK; Kim EJ; Song GS; Kim EY; Shin JG; Ghim JL; Kim HS
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):66-74. PubMed ID: 25034618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study.
    Choi Y; Lee S; Cho SM; Kang WH; Nam KY; Jang IJ; Yu KS
    Drug Des Devel Ther; 2016; 10():3021-3028. PubMed ID: 27703330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
    de Zeeuw D; Remuzzi G; Kirch W
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions.
    Tjandrawinata RR; Setiawati E; Yunaidi DA; Simanjuntak R; Santoso ID; Susanto LW
    Drug Des Devel Ther; 2013; 7():841-7. PubMed ID: 23990709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of long-acting nifedipine GITS/OROS monotherapy or combination therapy in hypertensive patients: results of a 12-week international, prospective, multicentre, observational study.
    Ueng KC; Ningling S; El Maksod A; Hung KY; Yuehui Y
    Clin Drug Investig; 2011; 31(9):631-42. PubMed ID: 21591818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses.
    Kjeldsen SE; Cha G; Villa G; Mancia G;
    J Clin Pharmacol; 2016 Sep; 56(9):1120-9. PubMed ID: 26829251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial.
    Mancia G; Cha G; Gil-Extremera B; Harvey P; Lewin AJ; Villa G; Kjeldsen SE
    J Hum Hypertens; 2017 Mar; 31(3):178-188. PubMed ID: 27511476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
    Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study.
    Park JB; Ha JW; Jung HO; Rhee MY;
    Blood Press Monit; 2014 Oct; 19(5):294-301. PubMed ID: 24915052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects.
    Kim JR; Kim S; Huh W; Ko JW
    Drug Des Devel Ther; 2018; 12():2475-2483. PubMed ID: 30127595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.